SI-BONE, Inc.
550 South Winchester Boulevard
Suite 620
San Jose
California
95128
United States
Tel: 408-207-0700
Fax: 408-557-8312
Website: http://www.si-bone.com/
Email: info@SI-BONE.com
168 articles about SI-BONE, Inc.
-
SI-BONE, Inc. Announces Anthem, Inc. Adopts Coverage Guidelines for Sacroiliac Joint Fusion Exclusive to the Triangular iFuse Implant System® for Its More Than 40 Million Members
8/2/2021
SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that Anthem, Inc. will cover minimally invasive SI joint fusion exclusively when performed with the iFuse system of triangular titanium implants.
-
SI-BONE to Present at the Canaccord Genuity 41st Annual Growth Conference
7/29/2021
SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming Canaccord Genuity 41st Annual Growth Conference.
-
SI-BONE To Report Second Quarter 2021 Financial Results on August 2, 2021
7/20/2021
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2021 after market close on Monday, August 2, 2021.
-
SI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse Implant System
7/14/2021
SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that Centene Corporation has established a positive coverage policy for minimally invasive SI joint fusion.
-
SI-BONE, Inc. Announces Publication of iFuse-3D Implant Clinical Study Results Showing Accelerated Fusion, Immediate and Sustained Clinical Improvements and Reduction in Opioid Use
7/7/2021
SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy announced the publication of 2-year results from SALLY 1, a prospective multicenter clinical trial of the iFuse-3D™ Implant System.
-
SI-BONE, Inc. Announces the Introduction of the SI-BONE SImulator™ Powered by Medability for iFuse Surgeon Training and Education
7/2/2021
SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the worldwide launch of the SI-BONE SImulator™.
-
French National Healthcare System Adopts Exclusive Reimbursement Policy for SI-BONE, Inc.’s iFuse-3D Implant System™Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years
6/15/2021
SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy announced that the French Health Ministry has granted national reimbursement for the iFuse-3D Implant System™.
-
SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference
6/8/2021
SI-BONE, Inc. (Nasdaq: SIBN), today announced that the company will be participating in the upcoming 2021 JMP Securities Life Sciences Conference.
-
SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance
5/3/2021
SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2021.
-
SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors
4/19/2021
SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company’s Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021.
-
SI-BONE To Report First Quarter 2021 Financial Results on May 3, 2021
4/15/2021
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2021 after market close on Monday, May 3, 2021.
-
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Issues 2021 Financial Guidance
3/8/2021
SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2020.
-
SI-BONE To Report Fourth Quarter and Full Year 2020 Financial Results on March 8, 2021
2/9/2021
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Monday, March 8, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
-
SI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue
1/7/2021
SI-BONE, Inc., a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors.
-
SI-BONE to Present at the 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference
12/17/2020
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 23 rd Annual Needham Growth Conference and the 39 th Annual J.P. Morgan Healthcare Conference. For the Needham Growth Conference, SI-BONE’s management is scheduled for a Fireside Chat on Monday, January 11, 2021 at 2:45 p.m. Eastern
-
SI-BONE, Inc. Announces that Humana Establishes Exclusive Coverage for iFuse in MIS SI Joint Fusion Procedures
12/16/2020
SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced that Humana has revised its coverage policies to cover minimally invasive SI joint fusion using triangular titanium implants (i.e., iFuse Implant System). Humana is one of the five largest commercial payers in the U.S., with over 12.7 million covered lives. The revised pol
-
SI-BONE Announces Pricing of Public Offering of Common Stock - Oct 15, 2020
10/15/2020
SI-BONE, Inc. announced the pricing of its underwritten public offering of 3,190,053 shares of its common stock at a price to the public of $22.00 per share.
-
SI-BONE Announces Launch of Public Offering of Common Stock - Oct 14, 2020
10/14/2020
SI-BONE, Inc., a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, announced that it has commenced an underwritten public offering of 3,190,053 shares of its common stock.
-
SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance
10/8/2020
SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the three and nine months ended September 30, 2020.
-
SI-BONE to Present at the 2020 Cantor Global Healthcare Conference
9/2/2020
SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming 2020 Cantor Global Healthcare Conference.